Patents by Inventor Ute Lander

Ute Lander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11246866
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: February 15, 2022
    Assignee: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Publication number: 20200282004
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: October 16, 2019
    Publication date: September 10, 2020
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Publication number: 20200253968
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: October 16, 2019
    Publication date: August 13, 2020
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Patent number: 10463739
    Abstract: A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 5, 2019
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Gunther Berndl, Juergen Weis, Dietrich Granzow, Bernd Liepold, Ute Lander, Ulrich Westedt
  • Publication number: 20190216882
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 18, 2019
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Patent number: 9616130
    Abstract: Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono-and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: April 11, 2017
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Jörg Rosenberg, Jörg Breitenbach, Kennan Marsh, Bernd Liepold, Christoph Schmidt, Ute Lander
  • Publication number: 20160375017
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: July 18, 2016
    Publication date: December 29, 2016
    Applicant: AbbVie Inc.
    Inventors: Katharina Asmus, Yi Gao, Colleen Garrett, Harald Hach, Adivaraha Jayasankar, Kyeremateng Samuel, Ute Lander, Thomas Mueller, Marius Naris, Constanze Obermiller, Regina Reul, Katrin Schneider, Nancy Sever, Michael Simon, Benedikt Steitz, Ping Tong, Ulrich Westedt, Donghua Zhu
  • Publication number: 20160375087
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 29, 2016
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Publication number: 20150314000
    Abstract: Pharmaceutically acceptable solubilizing compositions comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester are disclosed. The solubilizing compositions are useful in the manufacture of pharmaceutical dosage forms comprising a melt-processed mixture of at least one active ingredient and at least one pharmaceutically acceptable polymer. The solubilizing compositions enhance the bioavailability of the active ingredient following oral intake.
    Type: Application
    Filed: July 14, 2015
    Publication date: November 5, 2015
    Inventors: Jörg Rosenberg, Jörg Breitenbach, Kennan Marsh, Bernd Liepold, Christoph Schmidt, Ute Lander
  • Patent number: 9078921
    Abstract: A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: July 14, 2015
    Assignee: Abbvie Deutschland GmbH & Co KG
    Inventors: Jörg Rosenberg, Jörg Breitenbach, Kennan Marsh, Bernd Liepold, Christoph Schmidt, Ute Lander
  • Publication number: 20140296336
    Abstract: A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.
    Type: Application
    Filed: December 22, 2011
    Publication date: October 2, 2014
    Applicant: ABBOTT GMBH & CO. KG
    Inventors: Gunther Berndl, Juergen Weis, Dietrich Granzow, Bernd Liepold, Ute Lander, Ulrich Westedt
  • Publication number: 20100247635
    Abstract: A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake.
    Type: Application
    Filed: July 17, 2007
    Publication date: September 30, 2010
    Applicant: ABBOTT GMBH & CO. KG
    Inventors: Jörg Rosenberg, Jörg Breitenbach, Kennan Marsh, Bernd Liepold, Christoph Schmidt, Ute Lander
  • Publication number: 20070190142
    Abstract: A dosage form and method for the delivery of drugs, particularly drugs of abuse, characterized by resistance to solvent extraction, tampering, crushing, or grinding, and providing an initial burst of release of drug followed by a prolonged period of controllable drug release.
    Type: Application
    Filed: January 22, 2007
    Publication date: August 16, 2007
    Applicant: Abbott GmbH & Co. KG
    Inventors: Jorg BREITENBACH, Ute Lander, Jorg Rosenberg, Markus Maegerlein, Gerd Woehrle